NCT00387556View on ClinicalTrials.gov

Ondansetron Reduce Vomiting Associated With Ketamine PSA

NACompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Conscious Sedation
Interventions
DRUG

Ondansetron

ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)

Trial Locations (1)

80218

The Childrens Hospital, Denver

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT00387556 - Ondansetron Reduce Vomiting Associated With Ketamine PSA | Biotech Hunter | Biotech Hunter